Telomir plans Phase 1/2 trial of Telomir-Zn in triple-negative breast cancer after preclinical publication

• Telomir Pharmaceuticals highlighted a peer-reviewed preclinical publication on Telomir-Zn, positioning it to support a planned Phase 1/2 TNBC trial.
• Results have already been presented via the journal publication, not slated for a future medical meeting disclosure.
• Studies showed tumor growth suppression in prostate cancer and TNBC models, with activity tied to an iron-dependent mechanism.
• Data indicated selectivity for cancer cells over normal cells, with reduced metastatic spread in one TNBC model.
• Combination testing suggested stronger tumor reduction with paclitaxel in one model, while another TNBC model showed no response.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-036742), on August 10, 2026, and is solely responsible for the information contained therein.